Randomized phase II study comparing efficacy and safety of combination-therapy trastuzumab and docetaxel vs. sequential therapy of trastuzumab followed by docetaxel alone at progression as first-line chemotherapy in patients with HER2+ metastatic br (Q84097272)
Jump to navigation
Jump to search
scientific article published on 11 April 2011
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Randomized phase II study comparing efficacy and safety of combination-therapy trastuzumab and docetaxel vs. sequential therapy of trastuzumab followed by docetaxel alone at progression as first-line chemotherapy in patients with HER2+ metastatic br |
scientific article published on 11 April 2011 |
Statements
Randomized phase II study comparing efficacy and safety of combination-therapy trastuzumab and docetaxel vs. sequential therapy of trastuzumab followed by docetaxel alone at progression as first-line chemotherapy in patients with HER2+ metastatic breast cancer: HERTAX trial (English)
Paul Hamberg
Monique M E M Bos
Hans J J Braun
Jacqueline M L Stouthard
Gert A van Deijk
Frans L G Erdkamp
Iris N van der Stelt-Frissen
Marijke Bontenbal
Geert-Jan M Creemers
Johanneke E A Portielje
Johannes F M Pruijt
Olaf J L Loosveld
Willem M Smit
Erik W Muller
Paul I M Schmitz
Caroline Seynaeve
Jan G M Klijn
Dutch Breast Cancer Trialists' Group (BOOG)
11 April 2011